Skip to main content
Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: Clinically relevant CHK1 inhibitors abrogate wild-type and Y537S mutant ERα expression and proliferation in luminal primary and metastatic breast cancer cells

Fig. 3

Validation of the AZD7762 effect in MCF-7, Y537S, and Tam Res cells. Western blot (A-C) and relative densitometric (D) analyses of ERα expression levels in (A) MCF-7, (B) Y537S, and (C) Tam Res cells treated for 24 h with the indicated doses of AZD7762 (AZD). The loading control was done by evaluating vinculin expression in the same filter. Significant differences with respect to control (0) were obtained by unpaired two-tailed Student’s t-test. Data show the mean ± the standard deviations. **** p < 0.0001; *** p < 0.001. The number of replicates is given as solid dots in the bar graph. E Growth curve analyses in MCF-7, Y537S, and Tam Res cells were performed as indicated in the material and method section for 5 days with the indicated doses of AZD7762 (AZD). The graphs show the normalized cell index (i.e., cell number), which is detected with the xCelligence DP device and calculated at each time point with respect to the control sample. Each sample was measured in a quadruplicate. For details, please see the material and methods section. F The inhibitor concentration 50 (IC50) was calculated for each cell line at 5 days after initial treatment

Back to article page